Loading company…
NeogenTC develops tumor-infiltrating lymphocyte and TCR-modified T-cell therapies for cancer.
Founded in 2020 and based in Seoul, NeogenTC develops immune cell therapies using its own platform, including tumor-infiltrating lymphocyte and TCR-modified T-cell treatments. The company raised KRW 15 billion in Series A funding from DSC Investment, Quad Ventures, TS Investment, Seoul Investment Partners, Login Best, Tigris Investment, Cosine Investment and Cha Partners. It planned to expand its research facilities and develop TCR-T treatments targeting solid cancers.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in